TL;DR: UnitedHealthcare modified its UG/AG Panels Medicare Advantage coverage policy, effective November 2, 2025. Here's what billing teams need to do.
UnitedHealthcare updated its urogenital/anogenital (UG/AG) Panels medical policy for Medicare Advantage plans. The policy governs molecular syndromic panel testing for STIs and vaginitis, covering CPT codes 81513, 81514, 81515, and 0352U. The change clarifies when expanded panels are covered versus when only targeted testing will be reimbursed — and the distinction has real claim denial risk for labs and OB/GYN practices billing these codes in 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | UnitedHealthcare |
| Policy | Urogenital/Anogenital (UG/AG) Panels – Medicare Advantage Medical Policy |
| Policy Code | urogenital-anogenital-ug-ag-panels |
| Change Type | Modified |
| Effective Date | November 2, 2025 |
| Impact Level | High |
| Specialties Affected | OB/GYN, Infectious Disease, Clinical/Reference Labs, Urology, Women's Health |
| Key Action | Audit your panel billing against the high-risk documentation and targeted-vs-expanded panel criteria before billing claims with CPT 81513, 81514, 81515, or 0352U |
UnitedHealthcare UG/AG Panel Coverage Criteria and Medical Necessity Requirements 2025
The UnitedHealthcare UG/AG Panels coverage policy draws a sharp line between two clinical scenarios. Know which side your claim falls on before you submit.
Scenario one: High-risk STI exposure. When a patient has a documented high-risk experience — potential exposure to multiple sexually transmitted pathogens — an expanded panel is considered medically necessary even if the patient has no symptoms. The key word is "documented." The high-risk reason must appear clearly in the medical record. A vague note won't hold up on audit.
Scenario two: Specific signs and symptoms without high-risk exposure. If the clinical concern points to one or two pathogens, UHC expects a targeted panel — not an expanded one. The policy uses HSV as its example: if the presenting concern is genital lesions suggestive of herpes simplex virus, UHC expects only HSV-1 and HSV-2 testing. Running a full UG/AG panel in that scenario is not covered. This is where most claim denials will come from.
Vaginitis/vaginosis testing has its own rule. For the diagnosis of infectious vaginosis or vaginitis, the UnitedHealthcare UG/AG Panels coverage policy specifically requires that any panel — targeted or expanded — include at least two of the following: Gardnerella vaginalis, BV-associated bacteria such as Atopobium vaginae and/or Megasphaera species, Trichomonas vaginalis, or Candida species. A panel that doesn't meet this combination requirement won't satisfy medical necessity under this policy.
There is no CMS National Coverage Determination (NCD) for UG/AG panels. That means regional Medicare Administrative Contractor (MAC) rules apply where Local Coverage Determinations (LCDs) or Local Coverage Articles (LCAs) exist. This policy fills the gap for UnitedHealthcare Medicare Advantage members in states or territories where no LCD/LCA governs these tests — and it controls coverage criteria where existing LCDs are silent.
If your lab or practice spans multiple MAC jurisdictions, check whether an applicable LCD governs your region before relying solely on this UHC policy for UG/AG panel billing guidelines. Talk to your compliance officer if you're unsure which rule takes precedence.
Prior authorization requirements are not explicitly called out in this policy for UG/AG panels. But documentation requirements are strict enough that you should treat them with the same discipline. A missing or thin clinical note is functionally the same as a missing prior auth — the claim won't survive review.
UnitedHealthcare UG/AG Panel Exclusions and Non-Covered Indications
Expanded panels are not covered when a specific, limited pathogen concern is the primary clinical picture. This is the clearest exclusion in the policy, and it's worth understanding precisely.
If a patient presents with a classic symptom pattern that points to one or two organisms, UHC considers it not reasonable and necessary to run a broad syndromic panel. The policy uses HSV lesions as the benchmark example. The same logic applies to any similar scenario — if your documentation supports a narrow differential, don't submit a broad panel code and expect reimbursement.
Panels that fail the vaginitis combination rule are also not covered. A vaginitis panel that tests only for Candida species, without including at least one of the other required organisms, doesn't meet the criteria. The policy is explicit that the combination of at least two of the listed organisms is required.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| High-risk STI exposure (epidemiologic/potential exposure), even without symptoms | Covered | 81513, 81514, 81515, 0352U | High-risk reason must be clearly documented in the record |
| Specific signs/symptoms pointing to limited pathogens (e.g., HSV lesions) | Targeted panel only — expanded panel NOT covered | 81513, 81514, 81515, 0352U | Only test for the specific organisms supported by clinical findings |
| Infectious vaginosis/vaginitis diagnosis | Covered when combination criteria met | 81513, 81514, 81515, 0352U | Panel must include ≥2 of: Gardnerella vaginalis, BVAB (Atopobium vaginae and/or Megasphaera spp.), Trichomonas vaginalis, Candida spp. |
| Expanded panel for vaginosis/vaginitis without meeting combination criteria | Not covered | 81513, 81514, 81515, 0352U | Single-organism panels or panels missing required combination don't qualify |
| States/territories with applicable LCDs/LCAs | LCD/LCA governs | All codes above | Refer to MAC-specific local coverage determination first |
| States/territories with no applicable LCD/LCA or where LCD is silent | This UHC policy governs | All codes above | Follow criteria in this policy directly |
UnitedHealthcare UG/AG Panel Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your panel orders against the high-risk vs. targeted-panel split before November 2, 2025. Pull your recent claims for CPT 81513, 81514, 81515, and 0352U. For each, confirm the medical record clearly states whether the clinical situation was a high-risk exposure or a symptom-specific presentation. Claims missing that distinction are denial risks starting on the effective date. |
| 2 | Update your documentation templates for high-risk exposure encounters. The phrase "high-risk reason must clearly be documented" is a direct audit trigger. Work with your clinical team to ensure the ordering note explicitly states the basis for expanded panel testing. "Potential exposure to multiple STIs following high-risk sexual encounter" is the kind of language that will hold up. "STI screening" is not. |
| 3 | Check your vaginitis panel configurations against the combination criteria. For CPT 81514 and 81515 billing for vaginosis/vaginitis, confirm your panels include at least two of the required organisms. If your current panel configuration doesn't meet the combination rule, flag it now — not after you receive a wave of claim denials. |
| 4 | Run a MAC lookup for your service territories. CMS has no NCD for UG/AG panels. Your MAC's LCD or LCA controls coverage where one exists. For UHC Medicare Advantage members in LCD-covered regions, the LCD applies first. Get your compliance officer to confirm which rule governs each state you bill in. |
| 5 | Train your coding and clinical staff on the targeted-panel distinction. This is the most likely source of denials. If a provider orders CPT 81515 for a patient with classic HSV presentation, the claim will not survive medical necessity review. Build a checkpoint into your charge capture workflow that flags expanded panel codes when the diagnosis supports a targeted workup. |
| 6 | Don't assume prior authorization is the only gatekeeping mechanism. This policy uses documentation requirements to enforce medical necessity, not prior auth. Your denial prevention strategy needs to shift toward front-end documentation review — not just PA tracking. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for UG/AG Panels Under urogenital-anogenital-ug-ag-panels
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 81513 | CPT | Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers |
| 81514 | CPT | Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers including Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus spp. |
| 81515 | CPT | Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers including Candida spp. (C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata |
| 0352U | CPT (PLA) | Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of multiple organisms in vaginal-fluid specimens |
Note: Two additional code rows in the source data appear to have formatting issues — the code field contains description fragments rather than CPT code numbers. The four codes above (81513, 81514, 81515, 0352U) are the complete, verified codes from this policy. Do not bill unlisted codes based on truncated data.
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| A51.0 | Primary genital syphilis |
| A51.1 | Primary anal syphilis |
| A51.31 | Condyloma latum |
| A52.76 | Other genitourinary symptomatic late syphilis |
| A54.00 | Gonococcal infection of lower genitourinary tract, unspecified |
| A54.01 | Gonococcal cystitis and urethritis, unspecified |
| A54.02 | Gonococcal vulvovaginitis, unspecified |
| A54.03 | Gonococcal cervicitis, unspecified |
| A54.09 | Other gonococcal infection of lower genitourinary tract |
| A54.1 | Gonococcal infection of lower genitourinary tract with periurethral and accessory gland abscess |
| A54.21 | Gonococcal infection of kidney and ureter |
| A54.22 | Gonococcal prostatitis |
| A54.23 | Gonococcal infection of other male genital organs |
| A54.24 | Gonococcal female pelvic inflammatory disease |
| A54.29 | Other gonococcal genitourinary infections |
| A54.6 | Gonococcal infection of anus and rectum |
| A56.00 | Chlamydial infection of lower genitourinary tract, unspecified |
| A56.01 | Chlamydial cystitis and urethritis |
| A56.02 | Chlamydial vulvovaginitis |
| A56.09 | Other chlamydial infection of lower genitourinary tract |
| A56.11 | Chlamydial female pelvic inflammatory disease |
| A56.19 | Other chlamydial genitourinary infection |
| A56.2 | Chlamydial infection of genitourinary tract, unspecified |
| A56.3 | Chlamydial infection of anus and rectum |
| A59.00 | Urogenital trichomoniasis, unspecified |
| A59.01 | Trichomonal vulvovaginitis |
| A59.02 | Trichomonal prostatitis |
| A59.03 | Trichomonal cystitis and urethritis |
| A59.09 | Other urogenital trichomoniasis |
| A60.00 | Herpesviral infection of urogenital system, unspecified |
| A60.01 | Herpesviral infection of penis |
| A60.02 | Herpesviral infection of other male genital organs |
| A60.03 | Herpesviral cervicitis |
| A60.04 | Herpesviral vulvovaginitis |
| A60.09 | Herpesviral infection of other urogenital tract |
| A60.1 | Herpesviral infection of perianal skin and rectum |
| A60.9 | Anogenital herpesviral infection, unspecified |
| A63.0 | Anogenital (venereal) warts |
| B20 | Human immunodeficiency virus [HIV] disease |
| B37.31 | Acute candidiasis of vulva and vagina |
| B37.32 | Chronic candidiasis of vulva and vagina |
| B37.41 | Candidal cystitis and urethritis |
| B37.42 | Candidal balanitis |
| B37.49 | Other urogenital candidiasis |
| B37.89 | Other sites of candidiasis |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| D26.0 | Other benign neoplasm of cervix uteri |
| L29.2 | Pruritus vulvae |
| L29.3 | Anogenital pruritus, unspecified |
| N34.1 | Nonspecific urethritis |
| N34.2 | Other urethritis |
| N41.0 | Acute prostatitis |
| N41.3 | Prostatocystitis |
| N48.5 | Ulcer of penis |
| N76.0 | Acute vaginitis |
| N76.1 | Subacute and chronic vaginitis |
| N76.2 | Acute vulvitis |
| N76.3 | Subacute and chronic vulvitis |
| N76.5 | Ulceration of vagina |
| N76.6 | Ulceration of vulva |
| N76.82 | Fournier disease of vagina and vulva |
| N76.89 | Other specified inflammation of vagina and vulva |
| N77.1 | Vaginitis, vulvitis and vulvovaginitis in diseases classified elsewhere |
| N89.8 | Other specified noninflammatory disorders of vagina |
| N90.89 | Other specified noninflammatory disorders of vulva and perineum |
| N93.0 | Postcoital and contact bleeding |
| N93.8 | Other specified abnormal uterine and vaginal bleeding |
| O09.90 | Supervision of high risk pregnancy, unspecified, unspecified trimester (Effective 09/02/2025) |
| O09.91 | Supervision of high risk pregnancy, unspecified, first trimester (Effective 09/02/2025) |
| O09.92 | Supervision of high risk pregnancy, unspecified, second trimester (Effective 09/02/2025) |
| O09.93 | Supervision of high risk pregnancy, unspecified, third trimester (Effective 09/02/2025) |
| O98.711 | Human immunodeficiency virus [HIV] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIV] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIV] disease complicating pregnancy, third trimester |
The source data notes 39 additional ICD-10-CM codes beyond those listed above. Review the full policy at PayerPolicy for the complete code set.
Get the Full Picture for CPT 81513
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.